Earnings Call · Q3 FY2024·2024-11-09

Q3 24EPS +13.95%·Rev n/aQ2 24EPS +37.66%·Rev n/aQ1 24EPS -22.95%·Rev n/aQ4 23EPS +6.00%·Rev n/a⚠ consensus missing

Atea Pharmaceuticals, Inc. AVIR

Jonae Barnes — Investor Relations or Communications

Dr. Jean-Pierre Sommadossi — Chief Executive Officer

Dr. Janet Hammond — Clinical Development or Medical Affairs Executive

John Vavricka — Commercial or Market Access Executive

Dr. Arantxa Horga — Clinical Development or Medical Affairs Executive

Andrea Corcoran — Chief Financial Officer or Finance Executive

+1.7%1d on move date+1.3% vs SPY3d−3.2%5d−3.8%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AVIR calls or request research access.

More AVIR calls Browse calls Request research access